SynthesisClinical microbiology reviews2025
Drug-resistant
Synthesis in Clinical microbiology reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 againstVirulence · 2026Article
- Genetic profiling of biofilm-associated genes (bap, ompA, csuE, and blaPER-1) in Acinetobacter baumannii clinical isolates.Archives of microbiology · 2026Article
- Article
- Codelivering Polymyxin B and Phage Using Thermosensitive Hydrogel for Treating Carbapenem-ResistantACS omega · 2026Article
- Biotransformation-guided production of quinalizarin as an antibacterial agent against Acinetobacter baumannii.Applied microbiology and biotechnology · 2026Article
- Rapid delineation ofMicrobiology spectrum · 2026Article
- Review
- Exploratory Evaluation of Susceptibility Patterns of Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2026Article
- Genotypic and Phenotypic Resistance Profiles of InvasiveMicroorganisms · 2026Article
- Repurposing bleomycin against Acinetobacter baumannii HisG: computational, biophysical, and antibacterial evidence.Journal of computer-aided molecular design · 2026Article
- ConsistentAntimicrobial agents and chemotherapy · 2026Article
- Beyond minimum inhibitory concentration values: clinical and diagnostic challenges of colistin heteroresistance in Acinetobacter baumannii.Molecular biology reports · 2026Review
- Long-Term Trends in Antimicrobial Resistance Among Gram-Negative Clinical Isolates at Mubarak Al-Kabeer Hospital, Kuwait (2007-2022).Antibiotics (Basel, Switzerland) · 2026Article
- A mutation-aware proteomics approach for designing a multi-epitope vaccine against multidrug-resistantMicrobiology spectrum · 2026Article
- Article
- Active surveillance cultures and cohorting for carbapenem-resistantInfection control and hospital epidemiology · 2026Article
- Generation and Evaluation of a Multi-Epitope Vaccine AgainstVaccines · 2026Article
- Novel triphenylphosphonium-hydrazone salts: integrated experimental and computational insights into AChE inhibition and resistance-overcoming antimicrobial and antibiofilm potential.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Inside Enemy Lines: Adhesion, Invasion, and Intracellular Persistence ofPathogens (Basel, Switzerland) · 2026Review
- Intrathecal combined with intravenous eravacycline for the treatment of multisite carbapenem-resistantFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
SUMMARY
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.